Back to Search
Start Over
Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey
- Source :
- ESC Heart Failure, ESC Heart Failure, Vol 8, Iss 4, Pp 3369-3374 (2021)
- Publication Year :
- 2021
-
Abstract
- Aims The use of beta‐blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta‐blocker prescription through a nationwide survey. Methods and results From 11 referral centres, we retrospectively collected data of CA patients with a first evaluation after 2016 (n = 642). Clinical characteristics at first and last evaluation were collected, with a focus on medical therapy. For patients in whom beta‐blocker therapy was started, stopped, or continued between first and last evaluation, the main reason for beta‐blocker management was requested. Median age of study population was 77 years; 81% were men. Arterial hypertension was found in 58% of patients, atrial fibrillation (AF) in 57%, and coronary artery disease in 16%. Left ventricular ejection fraction was preserved in 62% of cases, and 74% of patients had advanced diastolic dysfunction. Out of the 250 CA patients on beta‐blockers at last evaluation, 215 (33%) were already taking this therapy at first evaluation, while 35 (5%) were started it, in both cases primarily because of high‐rate AF. One‐hundred‐nineteen patients (19%) who were on beta‐blocker at first evaluation had this therapy withdrawn, mainly because of intolerance in the presence of heart failure with advanced diastolic dysfunction. The remaining 273 patients (43%) had never received beta‐blocker therapy. Beta‐blockers usage was similar between CA aetiologies. Patients taking vs. not taking beta‐blockers differed only for a greater prevalence of arterial hypertension, coronary artery disease, AF, and non‐restrictive filling pattern (P
- Subjects :
- Male
medicine.medical_specialty
medicine.drug_class
Short Communication
Left
Diastole
Short Communications
Heart failure
030204 cardiovascular system & hematology
Beta‐blockers
Cardiac amyloidosis
Transthyretin
Ventricular Function, Left
NO
Coronary artery disease
03 medical and health sciences
Beta-blockers
0302 clinical medicine
Internal medicine
Cardiac amyloidosi
medicine
Diseases of the circulatory (Cardiovascular) system
Humans
Ventricular Function
Light chains
030212 general & internal medicine
Beta-blocker
Medical prescription
Beta blocker
Aged
Retrospective Studies
Light chain
Ejection fraction
business.industry
Atrial fibrillation
Italy
Prescriptions
Stroke Volume
Amyloidosis
medicine.disease
RC666-701
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- ESC Heart Failure, ESC Heart Failure, Vol 8, Iss 4, Pp 3369-3374 (2021)
- Accession number :
- edsair.doi.dedup.....fb31a7726bef375ae28a74de1df91c23